San Jose, CA-Laserscope has received FDA approval to market a high-power KTP laser system for photoselective vaporization of the prostate for the treatment of BPH. The product uses an 80-watt KTP/532 laser system and sterile, disposable, fiber-optic delivery devices. During the procedure, a miniature camera attached to an endoscope is inserted through the urethra to the prostate. A laser fiber is threaded through the endoscope to the area to be treated. The laser, which operates at 532 nm, is then used to vaporize excess tissue. The minimally invasive procedure can be performed on an outpatient basis, the company says.